2 completed, 1 recruiting, 1 terminated. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Recruiting 1, Terminated 1 |
| Phase 1 | 1 | Completed 1 |
Follow ANCA-associated Vasculitis: new trials by email Literature Review of ANCA-associated Vasculitis trials Research Report on ANCA-associated Vasculitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases BCMA-CD19 CAR-T therapy - Systemic Lupus Erythematosus, Inflammatory Myopathy | Phase 2 | Recruiting | Peking University People's Hospital | 50 | 2024-12-26 | 2025-04-02 |
| Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis BDB-001 injection, Cyclophosphamide, Glucocorticoids - ANCA-associated Vasculitis | Phase 1 / Phase 2 | Completed | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 93 | 2022-02-22 | 2025-08-07 |
| Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids, CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoids, Placebo, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids - ANCA-associated Vasculitis | Phase 2 | Completed | Amgen | 42 | 2015-02-04 | 2025-03-13 |
| Abatacept in ANCA Associated Vasculitis Abatacept (Orencia) - ANCA-associated Vasculitis | Phase 2 | Terminated | Imperial College London | 7 | 2007-11-01 | 2015-05-29 |
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (4) · Antiphospholipid Syndrome (1) · Behcet Syndrome (1) · Churg-Strauss Syndrome (1) · Granulomatosis with Polyangiitis (1) · Immunoglobulin G4-Related Disease (1) · Lupus Erythematosus, Systemic (1) · Microscopic Polyangiitis (1) · Myositis (1) · Purpura, Thrombotic Thrombocytopenic (1) · Scleroderma, Systemic (1) · Sjogren's Syndrome (1) · Vasculitis (1)
Autoimmune Diseases (4) · Cardiovascular Diseases (4) · Immune System Diseases (4) · Skin Diseases (4) · Skin Diseases, Vascular (4) · Skin and Connective Tissue Diseases (4) · Systemic Vasculitis (4) · Vascular Diseases (4) · Vasculitis (3) · Hemic and Lymphatic Diseases (2) · Nervous System Diseases (2) · Arthritis (1) · Arthritis, Rheumatoid (1) · Blood Coagulation Disorders (1) · Blood Platelet Disorders (1)
Cyclophosphamide (2) · Glucocorticoids (2) · Abatacept (1) · BDB001 (1) · Prednisone (1) · Rituximab (1) · avacopan (1)
Amgen (1) · Imperial College London (1) · Peking University People's Hospital (1) · Staidson (Beijing) Biopharmaceuticals Co., Ltd (1)
China (2) · Canada (1) · United Kingdom (1) · United States (1)
Alan Salama (1) · Minghui Zhao, Postdoc (1) · Zhanguo Li (1)